cobas HPV
Roche Molecular Systems, Inc. · Decision date Oct 27, 2026
What did the FDA decide?
This record documents a 30-Day Notice supplement (S066) to PMA P100020 for cobas® HPV, a human papillomavirus DNA detection kit (product code MAQ, microbiology). The stated purpose is "to change the manufacturing process for oligonucleotides," filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The notice concerns how oligonucleotide components are manufactured; the supplied fields do not specify which oligonucleotides, what the prior or revised process steps are, or what validation data support the change.
The identifier establishes this as a supplement to the existing P100020 approval, not a new approval of the whole system, and the notice is not an original PMA. Roche Molecular Systems, Inc. is the applicant, and the decision field reads OK30. That the notice reports a manufacturing process change does not by itself demonstrate safety or clinical effectiveness; the source fields contain no such findings.
FDA approval order statement
to change the manufacturing process for oligonucleotides
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Microbiology
- Decision date
- Oct 27, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P100020/S066
- Regulatory pathway
- PMA supplement
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MAQ
- Decision code
- OK30
- Decision date
- Oct 27, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- MAQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P100020. Subsequent supplements may change the device or its indications.
FDA decision timeline
P100020 · Original PMA
COBAS HPV TEST
P100020/S066 received
Application receipt date recorded by FDA.
P100020/S066 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P100020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
COBAS HPV TESTP100020 | Roche Molecular Systems, Inc. | PMA approval | Apr 19, 2011 | FDA |
Explore the linked device profile
Other records with product code MAQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
cobas HPVP190028/S026 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Alinity m HR HPVP230003/S019 | Abbott Molecular, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Alinity m HR HPVP230003 | Abbott Molecular, Inc. | PMA approval | Nov 1, 2023 | FDA |
| Roche Molecular Systems, Inc. | PMA approval | Apr 3, 2020 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- roche.com
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P100020/S066
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



